Related references
Note: Only part of the references are listed.Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib
Yllka Latifi et al.
BLOOD (2019)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
Csilla Fazakas et al.
FRONTIERS IN PHYSIOLOGY (2018)
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
Marianne G. Pouwer et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2018)
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
E. Hadzijusufovic et al.
LEUKEMIA (2017)
The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p
Masumi Sukegawa et al.
LEUKEMIA RESEARCH (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Pulmonary arterial hypertension induced by tyrosine kinase inhibitors
Jason Weatherald et al.
CURRENT OPINION IN PULMONARY MEDICINE (2017)
Vascular Complications of Diabetes
Joshua A. Beckman et al.
CIRCULATION RESEARCH (2016)
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Peng Wu et al.
DRUG DISCOVERY TODAY (2016)
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
Christophe Guignabert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue
Fabian Jacob et al.
PLOS ONE (2016)
The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state
Naif Alhawiti et al.
THROMBOSIS RESEARCH (2016)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
Delphine Rea et al.
HAEMATOLOGICA (2014)
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
Joost C. M. Uitdehaag et al.
PLOS ONE (2014)
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Allan Joaquim Lamontanara et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin
Yoshikiyo Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
The global pandemic of peripheral artery disease
Alan T. Hirsch et al.
LANCET (2013)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T. D. Kim et al.
LEUKEMIA (2013)
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
David Montani et al.
CIRCULATION (2012)
Nilotinib-Associated Vascular Events
Alfonso Quintas-Cardama et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting non-malignant disorders with tyrosine kinase inhibitors
Friedrich Grimminger et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Share Paper
